IDEXX Laboratories (IDXX) vs Oruka Therapeutics (ORKA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Oruka Therapeutics (ORKA) has outperformed IDEXX Laboratories (IDXX) over the past year, gaining 241.6% versus a loss of 18.5%. Over five years, ORKA leads with a +130.8% price change compared with -19.2% for IDXX. IDEXX Laboratories is the larger company by market cap ($40.81 billion vs $5.44 billion), about 7.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IDXX | ORKA |
|---|---|---|
| Share price | $518.00 | $82.11 |
| Market cap | $40.81B | $5.44B |
| 1-day change | +0.95% | +6.25% |
| YTD return | -24.15% | +154.97% |
| 1-year return | -18.54% | +241.64% |
| 5-year return | -19.21% | +130.82% |
| P/E ratio (TTM) | 36.40 | — |
| Forward P/E | 30.95 | — |
| EPS (TTM) | $14.23 | $-2.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.30B | — |
| Revenue growth (YoY) | +10.42% | — |
| Net income (latest FY) | $1.06B | $-105.43M |
| Gross margin | 61.80% | — |
| Operating margin | 31.60% | — |
| Net margin | 24.62% | — |
| 52-week high | $769.98 | $115.52 |
| 52-week low | $500.61 | $24.31 |
| Distance from 52-week high | -32.73% | -28.92% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +35.39% | +88.77% |
| Average volume | 553.95K | 896.59K |
| Shares outstanding | 78.78M | 66.21M |
| Employees | 11,000 | 68 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IDEXX Laboratories is about 7.5 times larger than Oruka Therapeutics by market value ($40.81B vs $5.44B).
- ORKA has outperformed IDXX by 260.2 percentage points over the past year.
About IDEXX Laboratories
IDXX stock →IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 11,000 employees
About Oruka Therapeutics
ORKA stock →Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 68 employees
IDXX vs ORKA FAQ
Which is bigger, IDEXX Laboratories or Oruka Therapeutics?
IDEXX Laboratories (IDXX) is larger, with a market capitalization of $40.81B compared with $5.44B for Oruka Therapeutics (ORKA).
Which stock has performed better over the past year, IDXX or ORKA?
ORKA returned +241.64% over the past 12 months, compared with -18.54% for IDXX (price return, excluding dividends). Past performance does not predict future results.
Are IDEXX Laboratories and Oruka Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.